BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xiao YD, Ma C, Zhang ZS, Liu J. Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience. Cancer Manag Res 2019;11:1551-7. [PMID: 30863165 DOI: 10.2147/CMAR.S193948] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Cai L, Li H, Guo J, Zhao W, Duan Y, Hou X, Cheng L, Du H, Shao X, Diao Z, Hao Y, Zheng X, Li C, Li W. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula. Cancer Biol Ther 2022;23:89-95. [PMID: 35230928 DOI: 10.1080/15384047.2021.2020059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Fan W, Zhu B, Zheng X, Yue S, Lu M, Fan H, Qiao L, Li F, Yuan G, Wu Y, Zou X, Wang H, Xue M, Li J. Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization. J Cancer Res Clin Oncol 2022. [PMID: 35788728 DOI: 10.1007/s00432-022-04107-w] [Reference Citation Analysis]
3 Lu HL, Xuan FF, Luo YC, Qin X. Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt. Abdom Radiol (NY) 2021;46:5417-27. [PMID: 34302511 DOI: 10.1007/s00261-021-03214-5] [Reference Citation Analysis]
4 Liu J, Zhang W, Lu H, Li H, Zhou X, Li J, Han X. Drug-eluting bead trans-arterial chemoembolization combined with microwave ablation therapy vs. microwave ablation alone for early stage hepatocellular carcinoma: a preliminary investigation of clinical value. J Cancer Res Clin Oncol 2021. [PMID: 34405295 DOI: 10.1007/s00432-021-03760-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Liang B, Makamure J, Shu S, Zhang L, Sun T, Zheng C. Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol 2021;11:576232. [PMID: 33796448 DOI: 10.3389/fonc.2021.576232] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
6 Tao PY, Zhang ZS, Wang TC, Yu MQ, Xiao YD. A predictive model of incomplete response after transarterial chemoembolization for early or intermediate stage of hepatocellular carcinoma: consideration of hepatic angiographic and cross-sectional imaging. Abdom Radiol (NY) 2021;46:581-9. [PMID: 32761406 DOI: 10.1007/s00261-020-02701-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Kim Y, Choi J. Imaging Anatomy for the Radiation Oncologist. Radiotherapy of Liver Cancer 2021. [DOI: 10.1007/978-981-16-1815-4_3] [Reference Citation Analysis]
8 Liu J, Xu J, Zhang W, Chen J, Zhou X, Li Z, Han X. Safety and Efficacy of Drug-Eluting Bead Transarterial Chemoembolization Combined with Apatinib in Patients with Advanced Hepatocellular Carcinoma. Acad Radiol 2020;27:704-9. [PMID: 31375353 DOI: 10.1016/j.acra.2019.07.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
9 Wang TC, Zhang ZS, Xiao YD. Determination of Risk Factors for Pain After Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma. J Pain Res 2020;13:649-56. [PMID: 32273750 DOI: 10.2147/JPR.S246197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Zhang ZS, Li HZ, Ma C, Xiao YD. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety. BMC Cancer 2019;19:1162. [PMID: 31783814 DOI: 10.1186/s12885-019-6386-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]